{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Community-acquired+Bacterial+Pneumonia",
    "query": {
      "condition": "Community-acquired Bacterial Pneumonia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Community-acquired+Bacterial+Pneumonia&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T14:23:06.679Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05629741",
      "title": "A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Community-acquired Pneumonia",
        "Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "CMTX-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clarametyx Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2022-11-14",
      "completion_date": "2024-08-02",
      "has_results": false,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 8,
      "location_summary": "Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05629741"
    },
    {
      "nct_id": "NCT01168713",
      "title": "Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Community-Acquired Bacterial Pneumonia"
      ],
      "interventions": [
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "CEM-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2010-08",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Flagstaff, Arizona • Bell Gardens, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "LeMesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01168713"
    },
    {
      "nct_id": "NCT05976581",
      "title": "Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pneumonia",
        "Pneumonia, Viral",
        "Pneumonia, Bacterial"
      ],
      "interventions": [
        {
          "name": "Electronic alert",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Structured communication of test results",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Jonathan Baghdadi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2023-11-01",
      "completion_date": "2025-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05976581"
    },
    {
      "nct_id": "NCT02269644",
      "title": "A P3 Comparator Trial in Community Acquired Bacterial Pneumonia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community Acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Linezolid Placebo",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-11",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-01-22",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 1,
      "location_summary": "Butte, Montana",
      "locations": [
        {
          "city": "Butte",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269644"
    },
    {
      "nct_id": "NCT05962606",
      "title": "Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Community-acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "AON-D21",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptarion Biotech AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 150,
      "start_date": "2024-02-02",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05962606"
    },
    {
      "nct_id": "NCT01524302",
      "title": "Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pneumonia, Bacterial",
        "Community-acquired"
      ],
      "interventions": [
        {
          "name": "Ceftaroline",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gary E. Stein, Pharm.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2012-02",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-12",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 1,
      "location_summary": "Lansing, Michigan",
      "locations": [
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524302"
    },
    {
      "nct_id": "NCT04160260",
      "title": "Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Community-acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Omadacycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paratek Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-11-28",
      "completion_date": "2020-04-13",
      "has_results": true,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • San Diego, California • Clearwater, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04160260"
    },
    {
      "nct_id": "NCT02735707",
      "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community-acquired Pneumonia, Influenza, COVID-19"
      ],
      "interventions": [
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin or Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Ceftaroline",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin-clavulanate",
          "type": "DRUG"
        },
        {
          "name": "Standard course macrolide",
          "type": "DRUG"
        },
        {
          "name": "Extended course macrolide",
          "type": "DRUG"
        },
        {
          "name": "No systemic corticosteroid",
          "type": "OTHER"
        },
        {
          "name": "Fixed-duration Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Shock-dependent hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration higher dose Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for influenza",
          "type": "OTHER"
        },
        {
          "name": "Five-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Lopinavir / Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine + lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Ivermectin",
          "type": "DRUG"
        },
        {
          "name": "No immune modulation for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Local standard venous thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "Conventional low dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Continuation of therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "No immunoglobulin",
          "type": "OTHER"
        },
        {
          "name": "Convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Delayed administration of convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "No vitamin C",
          "type": "OTHER"
        },
        {
          "name": "Vitamin C",
          "type": "DRUG"
        },
        {
          "name": "No antiplatelet",
          "type": "OTHER"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "No simvastatin",
          "type": "OTHER"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Eritoran",
          "type": "DRUG"
        },
        {
          "name": "Apremilast",
          "type": "DRUG"
        },
        {
          "name": "Clinician-preferred mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "Protocolised mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "No renin-angiotensin system inhibitor",
          "type": "OTHER"
        },
        {
          "name": "Angiotensin converting enzyme inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin Receptor Blockers",
          "type": "DRUG"
        },
        {
          "name": "ARB + DMX-200",
          "type": "DRUG"
        },
        {
          "name": "No cysteamine",
          "type": "OTHER"
        },
        {
          "name": "Cysteamine",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Baloxavir Marboxil",
          "type": "DRUG"
        },
        {
          "name": "Five-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "No endothelial modulator",
          "type": "OTHER"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "No Immune Modulator for Influenza",
          "type": "OTHER"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir + remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "UMC Utrecht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20000,
      "start_date": "2016-04-11",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 11,
      "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735707"
    },
    {
      "nct_id": "NCT05826873",
      "title": "Discharge Stewardship in Children's Hospitals",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pneumonia, Bacterial",
        "Pneumonia Childhood",
        "Urinary Tract Infections",
        "Soft Tissue Infections",
        "Skin Infections",
        "Community-acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Discharge antibiotic stewardship intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "28 Days to 18 Years"
      },
      "enrollment_count": 1131,
      "start_date": "2020-06-10",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 5,
      "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05826873"
    },
    {
      "nct_id": "NCT02559310",
      "title": "Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community Acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "lefamulin",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nabriva Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 551,
      "start_date": "2015-09",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-07-22T14:23:06.679Z",
      "location_count": 7,
      "location_summary": "Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more",
      "locations": [
        {
          "city": "Hazard",
          "state": "Kentucky"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Butte",
          "state": "Montana"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02559310"
    }
  ]
}